Chief, Endocrinology, North Shore Medical Center
Endocrinology
Paul Copeland practices Endocrinology. He went to Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine has a rank of 7 in research and a 57 in primary care He received awards:"Dr. Bennett I. Solomon Community Leadership Award", "Outstanding Clinical Practitioner Laureate Award" and "Regional Top Doctor". Paul M. Copeland, MD is a published physician. He published 45 publications, including: 'Inducible nitric oxide synthase demonstrated in allergic and irritant contact dermatitis.' Paul M. Copeland, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and l...
- An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated With atypical antipsychotics.
- No effect of adjunctive, repeated dose intranasal insulin treatment on body Metabolism in patients with schizophrenia.
- No Effect of Adjunctive, Repeated-Dose Intranasal Insulin Treatment on Psychopathology and Cognition in Patients With Schizophrenia.
- Metabolic effects of adjunctive aripiprazole in clozapine-treated patients With schizophrenia.
- Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients With schizophrenia.
- Effects of modafinil on weight, glucose and lipid Metabolism in clozapine-treated patients with schizophrenia.
- No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients With schizophrenia.
- Dietary saturated fat intake and glucose Metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone.
- Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients With schizophrenia treated With clozapine but not olanzapine.
- Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.
- Adrenal masses.
- Elevated hemoglobin A1c as a possible indicator of Diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics.
- Higher fasting serum insulin is associated With increased resting energy expenditure in nondiabetic schizophrenia patients.
- Adrenocortical carcinoma: contrast washout characteristics on CT.
- Glucose Metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model anal...
- Clozapine, Diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
- A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
- Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.
- Glucose Metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model...
- Management of the clinically inapparent Adrenal mass.
- Inducible nitric oxide synthase demonstrated in allergic and irritant contact dermatitis.
- Treatment of psoriasis With topical NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis.
- Treatment of psoriasis With topical sirolimus: preclinical development and a randomized, double-blind trial.
- An algorithm for the care of type 2 Diabetes.
- Diabetes mellitus and eating Disorders.
- Adrenal incidentaloma.
- Longitudinal follow-up of amenorrhea in eating Disorders.
- Two cases of therapeutic failure associated With levothyroxine brand interchange.
- Renal failure associated With laxative abuse.
- The incidentally discovered Adrenal mass.
- Hypoglycemia and death in anorexia nervosa.
- Bulimia nervosa--psyche and satiety.
- Effect of dexamethasone on cortisol and prolactin responses to meals in bulimic and normal women.
- Non-bulimia: food regurgitation in a patient With self-diagnosed bulimia.
- Cysteamine decreases prolactin responsiveness to thyrotropin-releasing Hormone in normal men.
- Neurochemical Abnormalities of anorexia nervosa and bulimia nervosa.
- Diuretic abuse and central pontine myelinolysis.
- Segmental norepinephrine and dopamine levels in cat spinal cord.
- Homocysteine levels and glucose Metabolism in non-obese, non-diabetic chronic schizophrenia.
- A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose Metabolism impairment in patients with schizophrenia.
- A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
- How successful are commercial weight-loss programs?
- Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.
Schools
Yale University School Of Medicine
Hospital Of The University Of Pennsylvania
Massachusetts General Hospital
Conditions Treated
- Abnormal Thyroid
- Acromegaly and Gigantism
- Adrenal Incidentaloma
- Adrenal Insufficiency
- View All
Doctors Specialties
Accepted Insurances
Awards
- Dr. Bennett I. Solomon Community Leadership Award
- Outstanding Clinical Practitioner Laureate Award
- Regional Top Doctor
Education
-
Massachusetts General Hospital
-
University of Pennsylvania Health System
-
Yale University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
NPI NUMBER |
|
1821044512 |
NPPES Provider LastName |
|
COPELAND |
NPPES Provider FirstName |
|
PAUL |
NPPES Provider ZIPCode |
|
01904 |
NPPES Provider State |
|
MA |
Specialty Description |
|
Endocrinology |
Total Claim Count |
|
4566.0 |
Distinct Opioid Count |
|
0.0 |
Opioid Claim Count |
|
0.0 |
Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
National Provider Identifier [NPI] |
1821044512 |
Last Name Of The Provider |
COPELAND |
First Name Of The Provider |
PAUL |
View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog